Literature DB >> 24633771

Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.

Xiaoli Bian1, Wangqing Dong, Yang Zhao, Rui Sun, Wanjun Kong, Yiping Li.   

Abstract

Activation of the phosphatidylinositol 3-kinase α (PI3Kα) is commonly observed in human cancer and is critical for tumor progression, which has made PI3Kα an attractive target for anticancer drug discovery. To systematically investigate the binding mode of A-66S, a new selective PI3Kα inhibitor for PI3Kα, molecular docking, molecular dynamics simulation and ensuing energetic analysis were performed. The binding free energy between PI3Kα and A-66S is -11.27 kcal•mol⁻¹ using MMPBSA method, while -14.67 kcal•mol⁻¹ using MMGBSA method, which is beneficial for the binding, and the van der Waals/hydrophobic and electrostatic interactions are critical for the binding. The conserved hydrophobic adenine region of PI3Kα made up of Met772, Pro778, Ile800, Tyr836, Ile848, Val850, Val851, Met922, Phe930 and Ile932 accommodates the flat 2-tert-butyl-4'-methyl-4,5'-bithiazol moiety of A-66S, and the NH of Val851 forms a hydrogen with the nitrogen atom embedded in the aminothiazole ring of A-66S. The (S)-pyrrolidine carboxamide urea moiety especially extends toward the region of the binding site wall (Ser854-Gln859) defined by the C-terminal lobe, and has three hydrogen-bond arms with the backbone of Ser854 and the side chain of Gln859. Notably the interaction between the non-conserved residue Gln859 and A-66S is responsible for the selectivity profile of A-66S. The binding mode of A-66S for PI3Kα presented in this study should aid in the design of a new highly selective PI3Kα inhibitor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633771     DOI: 10.1007/s00894-014-2166-z

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  32 in total

1.  A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations.

Authors:  Yong Duan; Chun Wu; Shibasish Chowdhury; Mathew C Lee; Guoming Xiong; Wei Zhang; Rong Yang; Piotr Cieplak; Ray Luo; Taisung Lee; James Caldwell; Junmei Wang; Peter Kollman
Journal:  J Comput Chem       Date:  2003-12       Impact factor: 3.376

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

Review 3.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

4.  Automatic atom type and bond type perception in molecular mechanical calculations.

Authors:  Junmei Wang; Wei Wang; Peter A Kollman; David A Case
Journal:  J Mol Graph Model       Date:  2006-02-03       Impact factor: 2.518

5.  Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.

Authors:  Jessica R Adams; Keli Xu; Jeff C Liu; Natalia M Ruiz Agamez; Amanda J Loch; Ruth G Wong; Wei Wang; Katherine L Wright; Timothy F Lane; Eldad Zacksenhaus; Sean E Egan
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

6.  Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.

Authors:  Jeffrey D Carson; Glenn Van Aller; Ruth Lehr; Robert H Sinnamon; Robert B Kirkpatrick; Kurt R Auger; Dashyant Dhanak; Robert A Copeland; Richard R Gontarek; Peter J Tummino; Lusong Luo
Journal:  Biochem J       Date:  2008-01-15       Impact factor: 3.857

7.  Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.

Authors:  Ana S Guerreiro; Sarah Fattet; Barbara Fischer; Tarek Shalaby; Shaun P Jackson; Simone M Schoenwaelder; Michael A Grotzer; Olivier Delattre; Alexandre Arcaro
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.

Authors:  Ming Han; John Z H Zhang
Journal:  J Chem Inf Model       Date:  2010-01       Impact factor: 4.956

9.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

10.  A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

Authors:  Stephen Jamieson; Jack U Flanagan; Sharada Kolekar; Christina Buchanan; Jackie D Kendall; Woo-Jeong Lee; Gordon W Rewcastle; William A Denny; Ripudaman Singh; James Dickson; Bruce C Baguley; Peter R Shepherd
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

View more
  1 in total

Review 1.  Recent Developments and Applications of the MMPBSA Method.

Authors:  Changhao Wang; D'Artagnan Greene; Li Xiao; Ruxi Qi; Ray Luo
Journal:  Front Mol Biosci       Date:  2018-01-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.